Vikas Sinha has served as Chief Financial Officer of Scholar Rock since April 2025. He brings over 30 years of executive leadership experience in the life sciences industry, with a proven track record across finance, investor relations, business development, strategy, IT, and human resources. Prior to joining Scholar Rock, he co-founded and served as CFO of ElevateBio, where he is currently a Board member. He also held the roles of President and CFO at AlloVir Inc.
Earlier in his career, Vikas served as CFO at Alexion Pharmaceuticals, where he played a pivotal role in the company’s growth—from a market capitalization of $600 million to over $30 billion, and from no revenue to more than $3 billion annually. Before Alexion, he held multiple leadership positions at Bayer AG across the United States, Japan, Germany, and Canada, including Vice President and CFO of Bayer Pharmaceuticals Corporation (U.S.) and Vice President and CFO of Bayer Yakuhin Ltd. (Japan).
Vikas currently serves as an independent board member and Audit Committee Chair at Verona Pharma. He is also a board member at Orna Therapeutics. He holds an MBA from the Asian Institute of Management in Manila, Philippines. He is a qualified Chartered Accountant and an associate member of the Institute of Chartered Accountants of India, as well as a Certified Public Accountant in the U.S.
What is Vikas Sinha's net worth?
The estimated net worth of Vikas Sinha is at least $26.23 million as of January 13th, 2026. Mr. Sinha owns 583,245 shares of Scholar Rock stock worth more than $26,228,528 as of January 19th. This net worth evaluation does not reflect any other investments that Mr. Sinha may own. Learn More about Vikas Sinha's net worth.
How do I contact Vikas Sinha?
Has Vikas Sinha been buying or selling shares of Scholar Rock?
During the last ninety days, Vikas Sinha has sold $715,438.50 in shares of Scholar Rock stock. Most recently, Vikas Sinha sold 16,755 shares of the business's stock in a transaction on Tuesday, January 13th. The shares were sold at an average price of $42.70, for a transaction totalling $715,438.50. Following the completion of the sale, the chief financial officer now directly owns 583,245 shares of the company's stock, valued at $24,904,561.50. Learn More on Vikas Sinha's trading history.
Who are Scholar Rock's active insiders?
Scholar Rock's insider roster includes Srinivas Akkaraju (Director), Jay Backstrom (President & CEO), Kristina Burow (Director), Jeffrey Flier (Director), Michael Gilman (Director), David Hallal (CEO), Junlin Ho (General Counsel & Corporate Secretary), Jing Marantz (Chief Medical Officer), Edward Myles (CFO), Caryn Parlavecchio (Insider), Katie Peng (Chief Commercial Officer, Denali Therapeutics), Mo Qatanani (Insider), Joshua Reed (Director), Tracey Sacco (Chief Commercial Officer), Vikas Sinha (CFO), Akshay Vaishnaw (President, R&D), Keith Woods (COO), and Keith Woods (COO). Learn More on Scholar Rock's active insiders.
Are insiders buying or selling shares of Scholar Rock?
In the last year, Scholar Rock insiders bought shares 3 times. They purchased a total of 530,038 shares worth more than $19,988,928.11. In the last year, insiders at the sold shares 27 times. They sold a total of 618,391 shares worth more than $24,126,909.07. The most recent insider tranaction occured on January, 14th when insider Mo Qatanani sold 13,112 shares worth more than $592,662.40. Insiders at Scholar Rock own 13.3% of the company.
Learn More about insider trades at Scholar Rock. Information on this page was last updated on 1/14/2026.
